Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Raised by Grandfield & Dodd LLC

Grandfield & Dodd LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 19.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,964 shares of the pharmaceutical company's stock after purchasing an additional 2,820 shares during the period. Grandfield & Dodd LLC's holdings in Vertex Pharmaceuticals were worth $6,831,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Dunhill Financial LLC grew its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Truvestments Capital LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, Sugar Maple Asset Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $35,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares of the company's stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 1,084 shares of company stock valued at $505,512 over the last 90 days. 0.20% of the stock is owned by company insiders.

Analyst Ratings Changes

VRTX has been the subject of a number of research reports. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Royal Bank of Canada lifted their price target on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. Piper Sandler decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Scotiabank lifted their price target on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research note on Tuesday, February 11th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $506.70.

Vertex Pharmaceuticals Trading Up 1.1 %

NASDAQ VRTX traded up $5.42 during mid-day trading on Wednesday, hitting $491.64. The company's stock had a trading volume of 1,147,335 shares, compared to its average volume of 1,495,791. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The stock's fifty day simple moving average is $445.18 and its two-hundred day simple moving average is $461.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market capitalization of $126.25 billion, a P/E ratio of -223.47, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.